摘要
目的:探讨唑来膦酸与伊班膦酸钠治疗骨肿瘤的临床效果,评估其用药安全性。方法:抽取的对象均就诊于2012年1月至2018年12月期间,共选取80例骨肿瘤患者,按照不同治疗方案,分为对照组和观察组(n=40)。对照组实施唑来膦酸治疗,观察组给予伊班膦酸钠治疗。比较患者临床治疗效果及不良反应情况;评估患者生活质量。结果:观察组患者临床总有效率显著高于对照组(P<0.05),观察组不良反应发生率明显低于对照组(P<0.05),观察组患者的社会功能、物质功能、心理功能及躯体功能评分均明显高于对照组(P<0.05)。结论:对于骨肿瘤患者给予伊班膦酸钠治疗,能取得显著的临床效果,不良反应少,安全可靠,提升患者整体的生活质量,具有积极的推广价值。
Objective: To investigate the clinical efficacy of zoledronic acid and ibandronate in the treatment of bone tumors, and to evaluate the safety of the drug. Methods: A total of 80 bone tumor patients were selected from January 2012 to December 2018, and were divided into control group and observation group according to different treatment regiments(n=40). The control group was treated with zoledronic acid and the observation group was treated with ibandronic acid sodium. To compare the clinical treatment effects and adverse reactions of patients;Assess the patient’s quality of life. Results: The total effective rate in the observation group was significantly higher than that in the control group(P<0.05), the incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05), and the scores of social, physical, psychological and physical functions in the observation group were significantly higher than that in the control group(P<0.05). Conclusion: The treatment of ibandronate sodium for bone tumor patients can achieve significant clinical effects, less adverse reactions, safety and reliability, improve the overall quality of life of patients, with positive promotion value.
作者
杨玉鹏
张志勇
YANG Yu-peng;ZHANG Zhi-yong(Department of Bone Oncology,Luoyang Zhenggu Hospital/Henan Province Orthopedic Hospital,Luoyang Henan 471000,China)
出处
《药品评价》
CAS
2019年第19期16-16,73,共2页
Drug Evaluation
关键词
骨肿瘤
唑来膦酸
伊班膦酸钠
安全性
Bone Tumor
Zoledronic Acid
Sodium Ibandronate
Security
